Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy

Human Gene Therapy Clinical Development

Volumn 28, Issue 4, 2017, Pages 187-196

  Fu, Haiyan ^a,b   Meadows, Aaron S ^a   Pineda, Ricardo J ^a   Kunkler, Krista L ^a   Truxal, Kristen V ^a,b   McBride, Kim L ^a,b   Flanigan, Kevin M ^a,b   McCarty, Douglas M ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

AAV; MPS III; pre existing Abs; seroprevalance

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ADOLESCENT; ARTICLE; CHILD; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENETIC VARIABILITY; HUMAN; MALE; PRIORITY JOURNAL; SANFILIPPO SYNDROME; SEROPREVALENCE; VIRAL GENE THERAPY; DEPENDOPARVOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOLOGY; PREVALENCE; SEROEPIDEMIOLOGY; SEROTYPE;

ANTIBODIES, VIRAL; CHILD; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MUCOPOLYSACCHARIDOSIS III; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; SEROGROUP;

EID: 85038634385     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2017.109     Document Type: Article

References (27)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 8th ed. New York: McGraw-Hill, 2001:3421-3452.
2. Fu H, Dirosario J, Killedar S, et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 2011;19:1025-1033.
3. Fu H, Cataldi MP, Ware TA, et al. Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery. Mol Ther Methods Clin Dev 2016;3: 16036.
4. Ruzo A, Marco S, Garcia M, et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 2012;23:1237-1246.
5. Haurigot V, Bosch F. Toward a gene therapy for neurological and somatic MPSIIIA. Rare Dis 2013; 1:e27209.
6. Rivera VM, Gao GP, Grant RL, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005;105:1424-1430.
7. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. New Engl J Med 2011; 365:2357-2365.
8. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
9. Nathwani AC, Rosales C, McIntosh J, et al. Longterm safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 2011;19:876-885.
10. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol2010;28:271-274.
11. Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65.
12. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009;17:1187-1196.
13. Mussche S, Devreese B, Nagabhushan Kalburgi S, et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther 2013;24:209-219.
14. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010;21:704-712.
15. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009;199:381-390.
16. Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006;107:1810-1817.
17. Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol 2013;4:341.
18. Wang L, Calcedo R, Bell P, et al. Impact of preexisting immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011;22:1389-1401.
19. Truxal KV, Fu H, McCarty DM, et al. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: implications for clinical trial design. Mol Genet Metab 2016;119: 239-248.
20. Murrey DA, Naughton BJ, Duncan FJ, et al. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev 2014;25:72-84.
21. Zygmunt DA, Crowe KE, Flanigan KM, et al. Comparison of serum rAAV serotype-specific antibodies in patients with Duchenne muscular dystrophy, Becker muscular dystrophy, inclusion body myositis, or GNE myopathy. Hum Gene Ther 2017;28:737-746.
22. Harrington EA, Sloan JL, Manoli I, et al. Neutralizing antibodies against adeno-associated viral capsids in patients with mut methylmalonic acidemia. Hum Gene Ther 2016;27:345-353.
23. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59:406-411.
24. Calcedo R, Morizono H, Wang L, et al. Adenoassociated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 2011;18:1586-1588.
25. Duncan FJ, Naughton BJ, Zaraspe K, et al. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice. Mol Ther 2015;23:638-647.
26. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004;78:6381-6388.
27. Velazquez VM, Meadows AS, Pineda RJ, et al. Effective depletion of pre-existing anti-AAV antibodies requires broad immune targeting. Mol Ther Methods Clin Dev 2017;4:159-168.